African Sleeping Sickness (HAT) ELISA Test
🧪 African Sleeping Sickness (Human African Trypanosomiasis, HAT) — ELISA Test Complete Guide
1. Overview of Human African Trypanosomiasis (HAT)
HAT is caused by the protozoan Trypanosoma brucei, transmitted via the tsetse fly (Glossina spp.).
Key points:
- Early infection may only affect blood and lymphatic system (Stage 1)
- Untreated cases progress to central nervous system (CNS) involvement (Stage 2), which can be fatal
- Endemic in sub-Saharan Africa
- WHO leads global control and surveillance initiatives
Serological testing, such as ELISA, plays a critical role in early detection and community surveillance.
2. Purpose of ELISA Testing for HAT
- Early Infection Detection
- Detects anti-Trypanosoma brucei antibodies in blood
- Effective during blood-stage infection
- Screening in Endemic Areas
- Targets high-risk populations: herders, farmers, residents of endemic regions
- Post-Treatment Monitoring
- Antibodies may persist for years
- Limited use for treatment response surveillance
- CNS Involvement Assessment
- ELISA positive → guides cerebrospinal fluid (CSF) analysis to determine Stage 2 infection
3. Specimen and Test Method (ELISA)
Specimen
- Serum (most common)
- Whole blood may be used in field rapid tests
Test Principle
- Microplate coated with Trypanosoma antigen
- Patient serum added → antibodies (if present) bind
- Enzyme-labeled secondary antibody added
- Substrate reaction produces color change
- Optical density (OD) measured → compared to cutoff value
Performance
- Sensitivity: 85–98%
- Specificity: 90–97%
- Varies by region and antigen type
4. Reference Ranges
| Result | Interpretation |
|---|---|
| OD < cutoff | Negative |
| OD ≥ cutoff | Positive |
| Near cutoff | Equivocal → repeat or confirm with other tests |
Note: ELISA detects antibodies; cannot always distinguish current vs past infection.
5. Clinical Significance
- Stage 1 Diagnosis (Blood/Lymphatic Stage)
- Antibodies rise rapidly during early infection
- Stage 2 Diagnosis (CNS Stage)
- ELISA alone cannot determine CNS involvement
- CSF examination required for treatment decisions
- Antibody Persistence
- Positive result may reflect past exposure
- Must interpret with exposure history and clinical signs
- Exposure History Essential
- Residence or travel in endemic areas
- Tsetse fly contact
6. Interpretation of Results
Positive (antibody detected)
- Possible T. b. gambiense or T. b. rhodesiense infection
- Past infection with residual antibodies
- Rarely, cross-reactivity with other parasitic infections
Negative
- May indicate window period (early infection)
- Immunosuppressed patients may not produce detectable antibodies
- Variant surface glycoproteins (VSG) may lead to non-detection
7. Key Considerations
- Not a standalone diagnostic
- Confirm with microscopy (blood/lymph aspirate), PCR, and CSF analysis
- Cross-reactivity caution
- Other parasitic or bacterial infections may cause false positives
- Post-treatment antibody persistence
- Positive ELISA does not always indicate active infection
- Risk assessment
- Consider patient residence, travel, and tsetse exposure
8. Summary Table
| Item | Key Points |
|---|---|
| Test Name | HAT ELISA (anti-Trypanosoma brucei antibodies) |
| Specimen | Serum (or whole blood in rapid field tests) |
| Principle | Antigen-antibody binding with enzyme colorimetric detection |
| Reference Range | OD < cutoff Negative / OD ≥ cutoff Positive |
| Clinical Use | Early infection detection, surveillance, screening high-risk populations |
| Limitations | Cannot confirm CNS stage; antibodies persist post-treatment; cross-reactivity possible |
9. References
- WHO. Control and Surveillance of Human African Trypanosomiasis. 2023 Guidelines
- Büscher P, et al. “Human African Trypanosomiasis: Diagnosis, Staging and Treatment.” Lancet Global Health
- Goodswen SJ, et al. “Trypanosoma brucei diagnostics: An overview.” Parasitology Research
- MacLean L, et al. “Serological Diagnosis of African Trypanosomiasis.” Tropical Medicine & International Health